Why the study?
Thrombotic risk is empirically considered low in oral squamous cell carcinoma patients despite limited data, which may lead to poor awareness of VTE prevention and increased morbidity and mortality.
This review highlights the potentially underrecognized risk of venous thromboembolism in patients with oral squamous cell carcinoma and the need for better awareness of VTE prevention in this population.
Venous thromboembolism (VTE) disease is the second leading cause of mortality in cancer patients. In the general population, the annual incidence of a thromboembolic event is about 117 cases per 100,000 persons, but cancer increases this risk about fourfold, while in patients receiving chemotherapy and surgical treatment, it is about sevenfold. Oral squamous cell carcinoma (OSCC) is the most common form of oral cancer and represents a multistep process in which environmental factors and genetic alterations are implicated. Thrombotic risk is considered empirically low in OSCC patients, although few data are available. Having limited information available may result in poor awareness of VTE prevention in OSCC, risking jeopardising the oncologic treatment and increasing the morbidity and mortality among these patients. In this paper, the topic of OSCC-associated thrombosis will be discussed.
No takes yet. Share an insight, caveat, or question.
Gennaro et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: